Upper Respiratory Tract Infection (URTI) — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2022 To 2032
The most frequent illness in humans is Upper Respiratory Tract Infection (URI), commonly known as the common cold. Key symptoms of URI encompass nasal congestion and discharge, sneezing, sore throat, and coughing. The presence of a mild fever is inconsistent and more prevalent in children compared to adults. The clinical manifestations show significant variation unrelated to specific viruses. Most mild symptoms include runny nose, sneezing, blocked and stuffy nose, postnasal drip, and cough. Additional indications like low-grade fever, sore throat, watery eye discharge, digestive discomfort, and overall unwellness might also manifest. Several familiar viruses responsible for URI are rhinovirus, coronavirus, adenovirus, respiratory syncytial virus (RSV), influenza, and parainfluenza virus. Transmission methods vary among these viruses, with RSV primarily spreading through contact with symptomatic children and contaminated objects, while influenza primarily spreads through airborne droplets. Although most URIs are brief, self-restricted infections confined to the upper airway, they can heighten airway sensitivity to irritants or secretions for weeks after the infection subsides. The underlying mechanisms likely involve a combination of mucosal invasion, chemical signaling molecules, and altered nerve reflexes. Additionally, URIs can impede pulmonary function by reducing metrics like FVC, FEV1, peak expiratory flow, and diffusion capacity. Complicated or severe URTIs include those accompanied by fever, productive cough, purulent secretions, lethargy, or wheezing. In such cases, patients should delay elective surgeries and reschedule them with a minimum gap of 4 weeks. On the other hand, uncomplicated or mild URTIs are typified by a clear runny nose, absence of fever, and an otherwise healthy appearance. Systemic medications are primarily employed to alleviate congestion and cough, yet their effectiveness is limited. Antihistamines and combinations of antihistamines with decongestants are common in over 800 over-the-counter (OTC) cold remedies.
Thelansis’s “Upper Respiratory Tract Infection (URTI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2022 To 2032” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Upper Respiratory Tract Infection (URTI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Upper Respiratory Tract Infection (URTI) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Upper Respiratory Tract Infection (URTI) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
